Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)

NCT01697579 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Fosaprepitant
DRUG: Fosaprepitant Placebo
DRUG: Ondansetron
DRUG: 5-hydroxytryptamine 3 antagonist

Sponsor

Merck Sharp & Dohme LLC